In Brief: FDA Hematology Division
FDA Hematology Division: Director Joseph Fratantoni, MD, leaves agency to join biologics consulting firm C.L. McIntosh & Associates as VP-biologics. Fratantoni has been director of the division since 1992 and has been involved in policymaking regarding Creutzfeldt-Jakob disease, blood substitutes and the review of erythropoietin...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth